DBVT
DBV Technologies S.A.
Next earnings Jul 27, 2026 · consensus $-0.10 EPS, $1.40M rev
Last earnings +3.4% on 2026-04-30
$16.02
▲ +2.69%$16.02▲ +70.43%
over 1Y
L $8.51EODHDH $24.54
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+2.7%
1W+3.2%
1M-11.8%
3M-20.7%
YTD-15.9%
1Y+70.4%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy
Pre-revenue biotech with one shot on goal (Viaskin Peanut) priced at $4.75B on $5.6M sales — speculative, not investable on fundamentals.
DBVT is a late-stage specialty biopharma whose entire equity story hinges on one asset: the Viaskin Peanut epicutaneous patch for pediatric peanut allergy. The 10-K MD&A is explicit that 2026's focus is 'commercialization and laying the groundwork to transform the lives of children living with peanut allergy' — meaning the company is still pre-approval, and the FY2025 revenue line of $5.64M is not a commercial business, it's residual/collaboration income. Putting a $4.75B market cap on that produces a P/S of 843.6x, which is not a valuation in any conventional sense — it is a probability-weighted bet on FDA approval and launch.
Sources: SEC EDGAR (CIK 0001613780, latest 10-Q filed 2026-04-30) · EODHD · analysis by claude-code · as of 6/25/2026, 2:33:33 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.